Report - Immune oncology vs. targeted therapies in solid tumors is ... · Tremelimumab Fully human IgG2 Phase III multiple tumors (HNSCC, NSCLC) IDO INCB024360 TKI Phase II multiple tumors

Please pass captcha verification before submit form